Placenta accreta spectrum (PAS) disorders are pathological attachment of the placenta to myometrium, where trophoblastic cells invade the uterine placental interface. PAS can lead to severe postpartum hemorrhage or even maternal death. Prenatal diagnosis of PAS is essential for optimal obstetric management to improve the pregnancy outcomes. However, in some low resource regions in China, less than 20% PAS are detected before delivery.
To explore the feasibility and universality of the bundled prevention and treatment strategy for placenta accreta spectrum disorders in different levels of medical institutions, and to investigate its effectiveness in improving the specialized disease management capabilities of medical institutions at all levels. We will conduct a regional, cluster-randomized trial to assess a multicomponent PAS management strategy to improve the prepartum detection rate of PAS.
Pregnant women who have regular prenatal examination at the research hospitals
Pregnant women diagnosed with PAS before or after delivery
Pregnant women who have never been diagnosed with placental implantation disease throughout the pregnancy
Pregnant women who were lost to follow-up during the study period
Pregnant women with placenta accreta spectrum disorders
Cohort
Prospective
Not listed
antepartum diagnosis rate of PAS
Click on the lead sponsor to view all of their trials.
Peking Union Medical College Hospital
Lead sponsor
National Key Research and Development Program of China
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
